Oasmia Pharmaceutical - Onwards and upwards
Oasmia is at a major inflection point as it focuses on its transformation into an R&D-driven, specialty pharma company, with commercially available assets. During 2020, with new management at the helm, much progress was made, including the global partnership deal with Elevar Therapeutics for lead oncology asset Apealea (Cremophor-free paclitaxel), and the implementation of significant cost saving programs. Management has kickstarted 2021 with the in-licensing of Cantrixil (in all indications) from Kazia Therapeutics for $4m upfront, the first of ‘a string of pearls’ strategy to bolster the oncology pipeline. Start of the Phase Ib docetaxel micellar trial in prostate cancer, divestment of the animal health business and optimisation of its platform technologies represent value drivers beyond Apealea. Our revised valuation is SEK2.84bn or SEK6.34/share.Oasmia Pharmaceutical develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. Co.'s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with alternatives, show improved properties, reduced side-effects, and expanded applications. Co.'s product development is based on its proprietary in-house research and company patents.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.